SLU-PP-915: Benefits, Research & Comparison with SLU-PP-332

What Is SLU-PP-915?

SLU-PP-915 is a synthetic pan-ERR agonist developed at Saint Louis University as part of an ongoing effort to create compounds capable of activating the entire estrogen-related receptor family. These nuclear receptors, commonly abbreviated as ERRs, are involved in regulating energy production, mitochondrial function, oxidative metabolism, and skeletal muscle adaptation.

Unlike estrogen receptors, estrogen-related receptors do not require estrogen binding to regulate gene transcription. Instead, they function as orphan nuclear receptors that coordinate hundreds of genes responsible for cellular energy production and metabolic flexibility. Because of this role, they have become attractive targets for scientists studying exercise mimetics and metabolic disease. [1]

The original lead compound developed by this research group was SLU-PP-332. While it demonstrated promising biological effects in animal studies, it suffered from poor oral bioavailability. Researchers therefore designed a chemically distinct successor capable of producing similar biological responses while also being effective when administered orally. This optimization ultimately led to the development of SLU-PP-915. [1]

Although excitement surrounding the molecule has increased, it remains important to remember that all currently published findings come from laboratory and animal experiments. There are currently no published clinical trials evaluating its safety or efficacy in humans. While some people put SLU-PP compounds in the same basket as peptides, it’s importan to note that this compound is not a peptide. If you understand what peptides are, you will easily understand the difference.

How Does SLU-PP-915 Work?

Activation of ERRα, ERRβ, and ERRγ Receptors

The primary mechanism behind SLU-PP-915 involves activation of the three major members of the estrogen-related receptor family: ERRα ERRβ and ERRγ.

These nuclear receptor proteins regulate genes involved in mitochondrial biogenesis, fatty acid oxidation, oxidative phosphorylation, and glucose metabolism. Rather than stimulating muscle growth directly, they help cells become more efficient at producing energy through aerobic pathways.

As an ERR agonist, the molecule increases transcriptional programs associated with endurance exercise. Because it activates multiple receptor isoforms simultaneously, it is classified as one of the newer ERR agonists rather than a selective ligand targeting only one receptor subtype.

Previous work on ERRγ agonists has shown that increased receptor signaling can improve oxidative muscle characteristics, enhance mitochondrial function, and support vascular remodeling in animal models. Those earlier discoveries helped establish the scientific rationale for developing broad-spectrum receptor activators like SLU-PP-915. [1]

Pan-ERR Agonist Activity and Cellular Signaling

The defining characteristic of SLU-PP-915 is its Pan-ERR agonist profile.

Instead of activating a single nuclear receptor, this Pan-ERR agonists approach allows coordinated regulation of multiple metabolic pathways at once. Researchers believe this broader receptor activation better reflects the complex biological changes normally triggered during endurance exercise.

One notable finding reported in mouse studies was increased expression of the Ddit4 gene after treatment. Ddit4 is commonly induced following aerobic exercise and has become an important biomarker when evaluating exercise mimetic activity. In several experiments, Ddit4 expression following SLU-PP-915 treatment matched or even exceeded the increase observed after treadmill running.

At the molecular level, investigators also examined changes in RNA expression to determine how the drug influenced downstream signaling pathways. These experiments demonstrated coordinated changes across several exercise-responsive genes, supporting continued investigation into the biological effects of ERR activation. [1]

Preclinical Research on SLU-PP-915

Interest in SLU-PP-915 has grown quickly because it appears to reproduce several molecular adaptations normally associated with endurance exercise. At the moment, however, every published study has been conducted in animals or laboratory systems. There are no human clinical trials available, which means any discussion of its potential should remain within the context of preclinical research.

Most of the available evidence comes from research groups at Saint Louis University led by Thomas Burris and colleagues, who have spent several years developing pan-ERR agonists as experimental exercise mimetics. Their work has focused on improving the pharmacological profile of earlier molecules while preserving the biological effects observed with activation of estrogen-related nuclear receptors. [1]

Rather than measuring a single biological endpoint, investigators evaluated multiple markers of metabolic adaptation. This included exercise performance, mitochondrial gene expression, plasma exposure, muscle energetics, and changes in receptor-regulated transcription. Looking at several endpoints together provides stronger data than relying on a single measurement alone, although it still does not establish effectiveness in humans.

In Vivo Research Findings

One of the most significant advances reported for SLU-PP-915 is its improved performance in vivo compared to earlier compounds.

Previous work demonstrated that SLU-PP-332 could substantially improve endurance capacity in mice, but its lack of oral bioavailability limited its usefulness for long-term experiments. Researchers addressed this limitation by developing 915, which maintained similar biological effects while also being effective after oral administration. [1]

In treadmill studies, mice treated with SLU-PP-915 showed approximately 50% improvements in running distance and running time compared with vehicle-treated controls. These improvements were comparable to those produced by 332, despite the newer molecule being administered at a lower dose during several experiments. The findings suggest that modifications to the chemical scaffold increased potency without sacrificing biological activity. [1]

Researchers also examined expression of the Ddit4 gene, which serves as a marker of acute aerobic exercise adaptation. Following administration of SLU-PP-915, Ddit4 expression increased substantially in skeletal muscle, with quadriceps tissue demonstrating an even greater response than that observed with SLU-PP-332. In some experiments, the increase approached levels produced by a one-hour treadmill running session. [1]

Additional experiments evaluated repeated oral dosing over seven days. Plasma concentrations increased proportionally with higher doses, while repeated administration did not appear t[1]  o result in excessive accumulation. Importantly, oral treatment continued to improve running performance and maintained activation of exercise-responsive genes throughout the study period.

Another interesting observation involved mitochondrial biology. Animals receiving SLU-PP-915 demonstrated increased mitochondrial DNA content together with higher expression of several mitochondrial genes. These findings are consistent with the established role of ERR signaling in regulating cellular energy production and oxidative metabolism. [1]

Although these findings are encouraging, they should not be interpreted as evidence that similar effects would occur in people. Mouse physiology differs substantially from human physiology, and many compounds that perform well during animal testing ultimately fail during clinical development.

Cell-Based Assays and Laboratory Analysis

Animal experiments represent only one part of the development process. Before researchers move toward larger studies, new molecules are also examined using cell-based assays and analytical chemistry techniques that help explain how the compound behaves after administration.

One recently published investigation focused on the metabolism of SLU-PP-915 using human liver microsomes and human liver S9 fractions. These laboratory systems allow scientists to estimate how a molecule may be transformed inside the body before human studies become available. [2]

The analysis identified seven Phase I metabolites for SLU-PP-915, while no Phase II conjugates were detected under the experimental conditions. For comparison, SLU-PP-332 produced nine metabolites, including both Phase I and Phase II products. This difference highlights how relatively small structural modifications can influence metabolic processing. [2]

To confirm the identity of several metabolites, investigators synthesized three of them and verified their structures using NMR spectroscopy alongside high-resolution mass spectrometry. Combining multiple analytical techniques increases confidence that the proposed metabolic pathways accurately reflect the transformations observed during laboratory testing. [2]

Researchers also examined how the compound fragmented during mass spectrometry, generating detailed metabolic maps that may eventually help anti-doping laboratories identify potential misuse if these molecules ever become commercially available. Because of their ability to enhance endurance-related physiology in animals, the authors suggested that both SLU-PP-915 and 332 may warrant future consideration in sports drug testing programs. [2]

Potential Research Applications

Because SLU-PP-915 is still an experimental molecule, discussions about its future use remain theoretical. Researchers are primarily interested in understanding how activation of estrogen-related receptors influences energy metabolism, mitochondrial function, and skeletal muscle biology. The compound is being used as a research tool to explore these pathways rather than as a treatment for any medical condition.

Several areas have attracted particular attention, including metabolic disorders, cardiovascular disease, muscle wasting conditions, and age-related declines in physical function. These possibilities are based on animal models and mechanistic studies rather than clinical evidence.

Metabolic Health and Mitochondrial Function

One reason researchers are interested in SLU-PP-915 is its ability to regulate genes involved in cellular energy production. Estrogen-related receptors serve as master regulators of mitochondrial metabolism, helping coordinate oxidative phosphorylation, fatty acid oxidation, and ATP production.

Activation of these pathways increases the cell’s ability to produce energy efficiently, particularly in tissues with high metabolic demands such as skeletal muscle and the heart. Previous research involving other pan-ERR agonists demonstrated improvements in mitochondrial gene expression, while studies with SLU-PP-915 reported similar increases together with greater mitochondrial DNA content in skeletal muscle. [1]

Researchers also observed increased expression of several mitochondrial genes following treatment, suggesting coordinated changes in RNA transcription downstream of ERR activation. These molecular adaptations resemble some of the transcriptional responses normally triggered during endurance exercise, although they do not replace the broad physiological benefits of regular physical activity.

Because impaired mitochondrial function contributes to numerous chronic diseases, compounds capable of influencing these pathways continue to receive considerable scientific attention.

Cellular Adaptation

Previous research has shown that estrogen-related receptors participate in regulating autophagy through transcription factors involved in lysosomal function. Proper regulation of this system helps maintain healthy muscle tissue by eliminating damaged cellular components and supporting mitochondrial quality control. While SLU-PP-915 has not been specifically shown to increase autophagy directly, activation of the same receptor pathways provides a biological rationale for continued investigation. [1]

Scientists are also interested in understanding how ERR activation interacts with signaling networks involving AMPK, PGC-1α, and other metabolic regulators. These pathways communicate through multiple proteins, including various kinase systems that coordinate cellular responses to energetic stress. These interactions may help explain why activation of a single nuclear receptor family can influence numerous biological processes simultaneously.

Thiophene Structure and Compound Characteristics

From a medicinal chemistry perspective, SLU-PP-915 represents more than simply an improved version of its predecessor.

The molecule belongs to a newer chemical series developed to optimize potency while improving oral exposure. Unlike SLU-PP-332, which suffers from poor oral bioavailability, 915 was intentionally designed using a distinct scaffold that produced more favorable pharmacokinetic properties during laboratory testing. [1]

Its structure incorporates a thiophene ring, a common feature in medicinal chemistry that can influence receptor binding, metabolic stability, and physicochemical characteristics. While structural modifications like this may appear minor, they often determine whether a molecule can progress beyond early discovery research.

As more pharmacological data become available, researchers will continue refining this class of compounds to improve selectivity, duration of action, and tissue targeting.

SLU-PP-915 vs SLU-PP-332

Although SLU-PP-915 and SLU-PP-332 belong to the same family of pan-ERR agonists, they represent different stages in the evolution of this research program.

SLU-PP-332 served as the original proof of concept. It demonstrated that pharmacological activation of ERR signaling could increase endurance, promote fatty acid oxidation, increase resting energy expenditure, reduce adiposity in obese mice, and improve several markers associated with metabolic syndrome. These studies established that exercise-like metabolic adaptations could be produced pharmacologically through ERR activation. [3]

Building on those findings, researchers developed SLU-PP-915 vs SLU-PP-332 with one major objective: maintaining the biological effects of 332 while overcoming its pharmacokinetic limitations.

The newer molecule uses a distinct chemical scaffold, demonstrates oral bioavailability, and produces exercise mimetic activity comparable to 332 in published animal studies. Investigators also reported stronger induction of Ddit4 in some skeletal muscles, together with comparable improvements in running distance and endurance at lower doses. [1]

The two compounds also differ in metabolism. Laboratory analysis identified seven metabolites for SLU-PP-915, whereas 332 generated nine metabolites, including several Phase II conjugates not observed with the newer molecule. These differences illustrate how relatively small structural modifications can substantially alter metabolic processing without changing the intended biological target. [2]

At present, neither molecule has entered clinical use. Both remain valuable research tools that continue to improve our understanding of estrogen-related receptor biology, exercise mimetics, and metabolic regulation.

Frequently Asked Questions

Is SLU-PP-915 approved for human use?

No. SLU-PP-915 is an investigational research compound. It has not been approved for medical use, and there are currently no published clinical trials evaluating it in humans.

Is SLU-PP-915 a peptide?

No. SLU-PP-915 is a chemically synthesized small-molecule nuclear receptor pan-agonist designed to mimic the physiological benefits of aerobic exercise.

What makes SLU-PP-915 different from SLU-PP-332?

Both compounds are pan-ERR agonists developed by the same research group. However, SLU-PP-915 was designed to improve on the pharmacological properties of its predecessor, particularly oral bioavailability, while maintaining similar biological activity in preclinical studies. [1]

What does SLU-PP-915 target?

SLU-PP-915 activates the estrogen-related receptor family, including ERRα, ERRβ, and ERRγ. These nuclear receptors regulate genes involved in mitochondrial function, fatty acid metabolism, and cellular energy production.

Is SLU-PP-915 an exercise mimetic?

Current evidence suggests that SLU-PP-915 reproduces several molecular and physiological adaptations associated with endurance exercise in animal models. However, these findings are limited to preclinical research, and it should not be considered a substitute for physical exercise or an established therapeutic intervention.